PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PepGen Inc. (PEPG) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (D+). The rating has held at C for 8 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.7) | C- (1.9) | B+ (3.6) | C+ (2.6) | C (2.5) |
| 2026-11-07 | C+ (2.5) | C- (1.9) | D (1.5) | B- (2.9) | C+ (2.7) | C (2.3) |
| 2026-10-31 | C+ (2.5) | D+ (1.8) | D (1.5) | B (3.3) | C+ (2.7) | C (2.3) |
| 2026-10-24 | C+ (2.5) | D+ (1.8) | D (1.5) | B+ (3.6) | C+ (2.6) | C (2.4) |
| 2026-10-17 | C+ (2.5) | D+ (1.8) | D (1.5) | B+ (3.6) | C+ (2.6) | C (2.4) |